This study addresses one of the contemporary challenges in breast cancer therapy, consisting in the identification of a subset of ER+ breast cancer patients having a high-risk of recurrence and tumor biomarkers being more accurate in the prediction of recurrence than standard clinical covariates. Here, ESR1 is linked to breast carcinoma.